Definite FG | Severe genital AEs | |
Total cases | 47 | 17 |
Reporter country (US/non-US) | 29/18 | 06/11/19 |
Age, years (mean/range)* | 58.9/38–78 | 50.7/35–70 |
Sex (M/F/)†† | 31/11 | 12/03/19 |
Type of SGLT2i | ||
Empagliflozin | 14 | 3 |
Dapagliflozin | 17 | 7 |
Canagliflozin | 16 | 7† |
Primary/secondary suspect | 47‡ | 16† |
Diabetes type | ||
Type 1 diabetes | 0 | 0 |
Type 2 diabetes | 25 | 10 |
Not specified | 7 | 1 |
Not reported | 15 | 6 |
Concomitant medications‡‡ | ||
Glucose-lowering agents | 21 | 7 |
Lipid-lowering agents | 7 | 3 |
Cardiovascular agents (including ASA) | 6 | 3 |
Systemic immunosuppressant drugs | 2§§ | 1 |
Systemic anti-infectives | 2 | 0 |
Levothyroxine | 2 | 0 |
Antiasthma | 1¶¶ | 0 |
Others | 11 | 3 |
None/not reported | 26 | 11 |
Mean time to onset, days (range)§ | 434 (0–2508) | 291 (0–965) |
Outcomes¶ | ||
Hospitalisation | 36 | 13 |
Life-threatening | 19 | 0 |
Disability | 5 | 2 |
Requiring intervention | 5 | 0 |
Death** | 2 | 0 |
Other | 14 | 6 |
*Not reported in 20 cases.
†In one case canagliflozin was reported as concomitant.
‡In one case dapagliflozin was reported as secondary suspect.
§Calculated for 27 reports with available data on ‘start date’ and ‘event date’. In case the specific day of start/event dates was not recorded, day 1 was imputed. Reports with incomplete data (both year and month of reporting) were excluded.
¶A report may be coded with multiple outcomes.
**One death was reported in the case narrative.
††Not reported in seven cases.
‡‡A report may contain multiple medications. If more than one drug of a given therapeutic class was reported (eg, glucose-lowering agents), the case counted only once.
§§In one case, secukinumab was reported as primary suspect drug.
¶¶Including a short-acting β2-adrenoreceptor agonist and a combination of inhaled corticosteroid and long-acting β2-adrenoreceptor agonist.
ASA, acetylsalicylic acid.